Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,369,000 | $11,142,000 | $10,358,000 | $10,974,000 |
| % Growth | 2% | 7.6% | -5.6% | – |
| Cost of Goods Sold | $5,031,000 | $4,854,000 | $4,914,000 | $5,376,000 |
| Gross Profit | $6,338,000 | $6,288,000 | $5,444,000 | $5,598,000 |
| % Margin | 55.7% | 56.4% | 52.6% | 51% |
| R&D Expenses | $785,000 | $732,000 | $703,000 | $728,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,103,000 | $3,093,000 | $3,053,000 | $2,880,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $420,000 | $411,000 | $0 | $0 |
| Operating Expenses | $4,308,000 | $4,236,000 | $3,756,000 | $3,608,000 |
| Operating Income | $2,030,000 | $2,052,000 | $1,688,000 | $1,990,000 |
| % Margin | 17.9% | 18.4% | 16.3% | 18.1% |
| Other Income/Exp. Net | $150,000 | $98,000 | $90,000 | $40,000 |
| Pre-Tax Income | $2,180,000 | $2,150,000 | $1,778,000 | $2,030,000 |
| Tax Expense | $536,000 | $371,000 | $453,000 | -$7,199,000 |
| Net Income | $1,644,000 | $1,779,000 | $1,325,000 | $9,229,000 |
| % Margin | 14.5% | 16% | 12.8% | 84.1% |
| EPS | 0.94 | 1.02 | 0.758 | 5.33 |
| % Growth | -7.8% | 34.5% | -85.8% | – |
| EPS Diluted | 0.94 | 1.01 | 0.758 | 5.27 |
| Weighted Avg Shares Out | 1,749,000 | 1,740,459 | 1,747,220 | 1,731,698 |
| Weighted Avg Shares Out Dil | 1,749,000 | 1,751,000 | 1,747,220 | 1,746,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $77,000 | $71,000 | $82,000 | $91,000 |
| Interest Expense | $44,000 | $121,000 | $134,000 | $152,000 |
| Depreciation & Amortization | $791,000 | $777,000 | $756,000 | $807,000 |
| EBITDA | $3,015,000 | $3,048,000 | $2,668,000 | $2,989,000 |
| % Margin | 26.5% | 27.4% | 25.8% | 27.2% |